117 related articles for article (PubMed ID: 19374036)
1. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
3. Sunitinib-induced pseudoporphyria.
Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
[No Abstract] [Full Text] [Related]
4. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Saylor PJ; Reid TR
J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
[No Abstract] [Full Text] [Related]
5. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
7. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
de Lima Lopes G; Rocha Lima CM
Pharmacotherapy; 2007 May; 27(5):775-7. PubMed ID: 17461715
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib and Thrombosis.
Lamba G; Deol R; Shah D; Sahni R; Malhotra BK
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S128-30. PubMed ID: 21881834
[No Abstract] [Full Text] [Related]
9. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome after treatment with sunitinib malate?
Mulherin B; Loconte NK; Holen KD
Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
[TBL] [Abstract][Full Text] [Related]
11. Acute severe hypothyroidism induced by sunitinib.
Prat A; Serrano C; Valverde C; Calvo E
Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
[No Abstract] [Full Text] [Related]
12. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Kefeli U; Buyuberber S; Akyol M; Yildiz R; Kaplan MA; Ciltas A; Sevinc A; Karaca H; Seker M; Ozdemir N; Alacacioglu A; Coskun U; Isikdogan A; Dane F; Gumus M; Ozkan M; Suner A; Tarhan MO; Benekli M
Hepatogastroenterology; 2013 Jun; 60(124):647-52. PubMed ID: 23165189
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
16. Transient sunitinib resistance in gastrointestinal stromal tumors.
Bracci R; Maccaroni E; Cascinu S
N Engl J Med; 2013 May; 368(21):2042-3. PubMed ID: 23697529
[No Abstract] [Full Text] [Related]
17. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
18. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
[No Abstract] [Full Text] [Related]
19. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor.
Bar-Sela G; Kedem E; Hadad S; Pollack S; Haim N; Atrash F; Shahar E
Jpn J Clin Oncol; 2010 Feb; 40(2):163-5. PubMed ID: 19797416
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sunitinib in an obese patient with a GIST.
Desar IM; Burger DM; Van Hoesel QG; Beijnen JH; Van Herpen CM; Van der Graaf WT
Ann Oncol; 2009 Mar; 20(3):599-600. PubMed ID: 19153120
[No Abstract] [Full Text] [Related]
[Next] [New Search]